CL2012001950A1 - Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño - Google Patents

Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño

Info

Publication number
CL2012001950A1
CL2012001950A1 CL2012001950A CL2012001950A CL2012001950A1 CL 2012001950 A1 CL2012001950 A1 CL 2012001950A1 CL 2012001950 A CL2012001950 A CL 2012001950A CL 2012001950 A CL2012001950 A CL 2012001950A CL 2012001950 A1 CL2012001950 A1 CL 2012001950A1
Authority
CL
Chile
Prior art keywords
medicament
humans
animals
manufacture
bacterial strain
Prior art date
Application number
CL2012001950A
Other languages
English (en)
Inventor
Bergonzelli Gabriela
Franz Isabelle Bureau
Rodenas Clara Lucia Garcia
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40785276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001950(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of CL2012001950A1 publication Critical patent/CL2012001950A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Uso de una cepa bacteriana probiótico en la fabricación de un medicamento o composición nutricional en humanos o animales para alterar los patrones del sueño.
CL2012001950A 2008-11-03 2012-07-12 Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño CL2012001950A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08168161 2008-11-03

Publications (1)

Publication Number Publication Date
CL2012001950A1 true CL2012001950A1 (es) 2013-01-11

Family

ID=40785276

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2011000891A CL2011000891A1 (es) 2008-11-03 2011-04-20 Uso de la cepa probiotica lactobacillus reuteri dsm17938 o una composicion nutricional que comprende una cepa bacteriana probiotica lactobacillus reuteri dsm17938 porque sirve para preparar un medicamento o una composicion nutricional util para reducir las alteraciones de sueño y/o mejorar la calidad del sueño o los patrones de sueño en humanos o animales.
CL2012001950A CL2012001950A1 (es) 2008-11-03 2012-07-12 Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2011000891A CL2011000891A1 (es) 2008-11-03 2011-04-20 Uso de la cepa probiotica lactobacillus reuteri dsm17938 o una composicion nutricional que comprende una cepa bacteriana probiotica lactobacillus reuteri dsm17938 porque sirve para preparar un medicamento o una composicion nutricional util para reducir las alteraciones de sueño y/o mejorar la calidad del sueño o los patrones de sueño en humanos o animales.

Country Status (16)

Country Link
US (3) US9034314B2 (es)
EP (2) EP2352393A1 (es)
CN (2) CN102202527B (es)
AU (1) AU2009319257B2 (es)
BR (1) BRPI0921617A2 (es)
CA (1) CA2742476A1 (es)
CL (2) CL2011000891A1 (es)
ES (1) ES2771176T3 (es)
MX (1) MX2011004142A (es)
MY (1) MY160376A (es)
PH (1) PH12014501749A1 (es)
PT (1) PT2438821T (es)
RU (2) RU2642301C9 (es)
TW (1) TW201029583A (es)
WO (1) WO2010060722A1 (es)
ZA (1) ZA201206546B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784798B2 (en) * 2009-05-11 2014-07-22 Nestec S.A. Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
JP5923238B2 (ja) * 2010-07-07 2016-05-24 アサヒグループホールディングス株式会社 迷走神経活性化剤
AU2012221154B2 (en) * 2011-02-23 2015-12-10 Biogaia Ab Indirect substrates for microorganisms metabolizing 1,2-propanediol
EP2734049B1 (en) 2011-06-20 2018-05-02 H.J. Heinz Company Brands LLC Probiotic compositions and methods
ES2795665T3 (es) * 2012-09-14 2020-11-24 Abbott Lab Procedimientos para aumentar la funcionalidad cerebral utilizando 2-fucosil-lactosa
EP2708145B1 (en) 2012-09-14 2016-05-04 Abbott Laboratories Nutritional compositions for use in methods for modulating corticosterone levels in psychologically stressed individuals
NZ714202A (en) 2013-05-10 2021-07-30 Heinz Co Brands H J Llc Probiotics and methods of use
GB201319538D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319539D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
GB201319540D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319531D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
PL235821B1 (pl) * 2014-11-04 2020-11-02 Geo Poland Spolka Z Ograniczona Odpowiedzialnoscia Wysokoprolinowy kompleks peptydowy do zastosowania w profilaktyce i wspomaganiu leczenia zaburzeń i stanów wymagających podwyższania i/lub modulacji poziomu neurotropowego czynnika pochodzenia mózgowego jako oznaczonego w osoczu krwi biomarkera i zawierający go preparat
JP2018528938A (ja) * 2015-08-31 2018-10-04 ネステク ソシエテ アノニム 情動的反応を制御するため、並びに潜在的な気分変調の治療及び予防のための、ビフィドバクテリウム・ロンガムを用いる、方法及び組成物
WO2017037105A1 (en) * 2015-08-31 2017-03-09 Nestec S.A. Methods and compositions using bifidobacterium longum to optimize breastfeeding
HK1263323A1 (zh) * 2015-08-31 2020-04-17 Société des Produits Nestlé S.A. 使用长双歧杆菌治疗或预防抑郁症状的方法和组合物
WO2017131402A1 (ko) * 2016-01-28 2017-08-03 경희대학교 산학협력단 면역조절 작용을 가는 사람 소화관 유래 신규 유산균 및 이의 용도
SMT202300283T1 (it) * 2016-04-15 2023-11-13 Baylor College Medicine Lactobacillus reuteri mm4-1a per l’uso nel trattamento o nella prevenzione dei disturbi dello spettro autistico
CN109310716A (zh) * 2016-07-01 2019-02-05 雀巢产品技术援助有限公司 用于预防和/或治疗哺乳动物的焦虑症及相关病症的包含益生菌的营养组合物
KR20180019474A (ko) * 2016-08-16 2018-02-26 주식회사 엠디헬스케어 락토바실러스 플란타룸 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물
BR112019020443A2 (pt) * 2017-05-05 2020-04-28 Nestle Sa tratamento de cólica em bebês
US11872238B2 (en) 2017-05-24 2024-01-16 Societe Des Produits Nestle S.A. Nutritional composition for use to enhance attention and/or reduce impulsivity
KR102591869B1 (ko) * 2017-06-02 2023-10-19 유니버시티 오브 오타고 산후 우울증 및 산후 불안 중 적어도 하나를 처치하거나 예방하기 위한 락트산 박테리아의 용도
US11439675B2 (en) 2017-07-07 2022-09-13 President And Fellows Of Harvard College Method for treating damage induced by sleep deprivation
EP3664894B1 (fr) 2017-08-11 2021-09-29 Biocodex Saccharomyces boulardii pour le traitement des troubles de l'humeur
MX2020002314A (es) 2017-08-30 2020-10-05 Shawn TALBOTT Suplementos nutricionales que afectan el equilibrio del eje intestino-cerebro y el bienestar mental.
CN107712905A (zh) * 2017-11-10 2018-02-23 无比滴（广东）药业有限公司 一种液体益生菌口服液
KR102250597B1 (ko) * 2017-11-20 2021-05-11 경희대학교 산학협력단 신규 유산균 및 이의 용도
WO2019098810A2 (ko) * 2017-11-20 2019-05-23 경희대학교 산학협력단 신규 유산균 및 이의 용도
US11679135B2 (en) 2017-12-19 2023-06-20 Probiotical S.P.A. Composition for use in the treatment and/or improvement of sleep and mood disorders
JP7303811B2 (ja) 2017-12-19 2023-07-05 デュポン ニュートリション バイオサイエンシーズ エーピーエス 認知的及び精神的健康のためのプロバイオティクス
TWI731209B (zh) * 2018-01-09 2021-06-21 柯順議 益生菌組合物及其用途
WO2019145573A1 (en) * 2018-01-29 2019-08-01 Alimentary Health Limited Bifidobacterium longum ncimb 41676
US11771723B2 (en) 2018-01-29 2023-10-03 Precisionbiotics Group Limited Bifidobacterium longum NCIMB 41676
WO2019145570A1 (en) 2018-01-29 2019-08-01 Alimentary Health Limited A combination product for prophylaxis and treatment of irritable bowel syndrome
BR112020015599A2 (pt) 2018-02-02 2021-01-05 Kobiolabs, Inc. Cepa de lactobacillus plantarum kbl396 e uso da mesma
IT201800003128A1 (it) * 2018-02-28 2019-08-28 Propharma Soc A Responsabilita Limitata Semplificata Composizione probiotica
CN108186688B (zh) * 2018-03-09 2021-03-16 华大精准营养（深圳）科技有限公司 一种促进睡眠的组合物
PL3777869T3 (pl) * 2018-03-28 2024-12-16 Morinaga Milk Industry Co., Ltd. Kompozycja wspierająca sen oraz kompozycja lecznicza oraz kompozycja żywności i napoju wykorzystujące wspomnianą kompozycję wspierającą sen
CN108823125A (zh) * 2018-06-13 2018-11-16 山东巴元生物科技有限公司 一种治疗睡眠障碍益生菌制剂的生产方法及应用
IL305597B2 (en) 2018-07-24 2024-08-01 Biogaia Ab Selection and use of melatonin-supporting bacteria to reduce infantile tinea
CN108949640B (zh) * 2018-08-22 2020-08-04 江南大学 短双歧杆菌ccfm1025、其发酵食品及其应用
AU2019363061A1 (en) 2018-10-17 2021-04-29 Frieslandcampina Nederland B.V. Sleep-improving compositions
CN109349645A (zh) * 2018-10-30 2019-02-19 广州普维君健药业有限公司 益生菌组合物、保健食品及其制备方法和应用
AU2019411230B2 (en) * 2018-12-21 2025-04-17 Société des Produits Nestlé S.A. Nutritional composition for inducing a feeling of satiety, a better sleep and/or limiting nocturnal awaking in infants or young children
CN113423288A (zh) * 2019-02-04 2021-09-21 N·V·努特里奇亚 用于睡眠改善的含有不可消化的低聚糖的发酵配方物
CN111297915B (zh) * 2019-04-12 2021-11-23 首都医科大学附属北京友谊医院 治疗帕金森病快速眼动期睡眠行为障碍的益生菌组合物、制剂及用途
CN110200285A (zh) * 2019-07-23 2019-09-06 河北一然生物科技有限公司 混合益生菌那曲4580(Nagqu 4580)在改善睡眠质量的食品中的应用
CN110339218A (zh) * 2019-08-14 2019-10-18 牛占锋 一种益生菌组合物及其在改善睡眠紊乱中的应用
MX2022002767A (es) 2019-09-04 2022-07-04 Amare Global Complementos nutricionales y métodos de complementación nutricional que afectan al humor y a la concentración en niños.
AU2020343033A1 (en) * 2019-09-04 2022-04-14 Amare Global Nutritional supplements and methods of nutritional supplementation affecting microbiome metabolism
WO2021046450A1 (en) 2019-09-04 2021-03-11 Amare Global Nutritional supplements and methods of supplementation affecting the endocannabinoid system
WO2021046459A1 (en) 2019-09-04 2021-03-11 Amare Global Nutritional supplements and methods of nutritional supplementation affecting heart/brain axis
JP6873291B1 (ja) * 2020-02-05 2021-05-19 雪印メグミルク株式会社 睡眠促進用組成物及び組成物を含む食品、医薬品、飼料
WO2022117830A1 (en) * 2020-12-04 2022-06-09 Société des Produits Nestlé S.A. Compositions comprising human milk oligosaccharides for use in a subject to support maturation of sleeping patterns
CN115299609A (zh) * 2022-03-21 2022-11-08 浙江臻叶茶业有限公司 一种具有改善睡眠功能的组合物及其制备方法
CN115025131B (zh) * 2022-06-02 2023-06-30 广东南芯医疗科技有限公司 罗伊氏乳杆菌e9在制备缓解焦虑、改善睡眠药物中的应用
CN115226773A (zh) * 2022-06-29 2022-10-25 湖北明慧健康科技有限责任公司 一种复合益生菌助眠固体饮料及其制备方法
CN116121130B (zh) * 2022-12-23 2024-10-08 中科宜康（北京）生物科技有限公司 一种提高睡眠质量的复合益生菌发酵组合物及应用
CN116656549B (zh) * 2023-05-25 2023-11-14 微康益生菌(苏州)股份有限公司 一种能够改善睡眠质量的益生菌剂及其应用
WO2025132298A1 (en) * 2023-12-19 2025-06-26 Société des Produits Nestlé S.A. Compositions for promoting sleep in a young individual
CN118576619B (zh) * 2024-08-06 2024-11-22 深圳奥萨制药有限公司 一种含有维生素和矿物质的组合物
CN119350467B (zh) * 2024-12-09 2025-04-04 北京璟嘉生物科技有限公司 一种益生菌的组合物、制备方法及其在促进睡眠中的应用
CN120131938B (zh) * 2025-03-19 2025-12-23 广州奥奇生物技术有限公司 一种益生菌制剂的制备方法及其在改善睡眠中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM864894A0 (en) * 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US6444203B2 (en) * 1999-12-20 2002-09-03 Compagnie Gervais Danone Administering bacteria to improve sleep
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20050100531A1 (en) * 2002-06-13 2005-05-12 John Bienenstock Probiotic therapies
JP4874532B2 (ja) * 2004-08-25 2012-02-15 株式会社琉球バイオリソース開発 睡眠改善剤
JP2006160697A (ja) 2004-12-10 2006-06-22 Kao Corp 睡眠健康改善剤
JP4344827B2 (ja) 2005-11-28 2009-10-14 国立大学法人九州大学 スキゾキトリウム属の微生物を用いた長鎖高度不飽和脂肪酸含有リン脂質の製造方法
CA2642431A1 (en) * 2006-02-15 2007-08-23 Nestec S.A. Use of bifidobacterium longum for the prevention and treatment of inflammation
US7374924B2 (en) 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
WO2007150052A1 (en) * 2006-06-23 2007-12-27 Equine Research Associates, Ltd Animal nutritional supplement and method
JP2008137941A (ja) * 2006-12-01 2008-06-19 Mitsukan Group Honsha:Kk 睡眠改善用組成物
US20080176305A1 (en) * 2006-12-20 2008-07-24 Kikkoman Corporation Functional composition
WO2008106373A1 (en) * 2007-02-28 2008-09-04 Mead Johnson Nutrition Company Product containing inactivated probiotic for children or infants
UA28995U (en) 2007-09-24 2007-12-25 Sanitary and hygienic product
EP2110028A1 (en) * 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression

Also Published As

Publication number Publication date
CL2011000891A1 (es) 2011-09-16
CA2742476A1 (en) 2010-06-03
US9034314B2 (en) 2015-05-19
RU2517616C2 (ru) 2014-05-27
MX2011004142A (es) 2011-05-25
PH12014501749B1 (en) 2016-01-18
RU2011122453A (ru) 2012-12-10
ES2771176T3 (es) 2020-07-06
EP2438821B1 (en) 2020-01-15
AU2009319257A1 (en) 2010-06-03
CN102202527B (zh) 2014-12-31
PT2438821T (pt) 2020-04-22
PH12014501749A1 (en) 2016-01-18
US20140242050A1 (en) 2014-08-28
TW201029583A (en) 2010-08-16
EP2438821A1 (en) 2012-04-11
ZA201206546B (en) 2022-03-30
EP2352393A1 (en) 2011-08-10
RU2642301C9 (ru) 2018-06-27
WO2010060722A1 (en) 2010-06-03
RU2642301C2 (ru) 2018-01-24
CN102960447A (zh) 2013-03-13
MY160376A (en) 2017-03-15
US20140212389A1 (en) 2014-07-31
CN102202527A (zh) 2011-09-28
RU2013137772A (ru) 2015-02-20
BRPI0921617A2 (pt) 2015-08-18
US20110206649A1 (en) 2011-08-25
AU2009319257B2 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
CL2012001950A1 (es) Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CR20110609A (es) Composicion antimicrobiana y metodos relacionados de uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
UY31484A1 (es) Piperidinas heteroaril-sustituidas
BRPI0616866A8 (pt) Enterococos probióticos para melhorar a imunidade
AR085943A1 (es) Composicion antimicrobiana
BRPI0816128A2 (pt) Uso de uma composição de estabilização, composição de estabilização, produto de cuidado corporal, e, produto doméstico.
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
UY31136A1 (es) Oxazolidinonas sustituidas y su uso
MX2010005006A (es) Producto para el cuidado oral y metodos de uso y fabricacion del mismo.
AR053803A1 (es) Uso de acido pinolenico
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
CL2013001853A1 (es) Bacteria no patogena gram negativa perteneciente a la clase betaproteobacteria y subfamilia neisseriaceae; extracto que la comprende; composicion que comprende a la bacteria o al extracto; y su uso para tratar o prevenir trastornos inflamatorios dermatologicos.
DOP2009000285A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulacion sanguinea.
AR082215A1 (es) Composicion farmaceutica agradable al paladar
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
UY31903A (es) 7-sulfanilmetil-,7-silfinilmetil-y7-sulfonilmetilindoles sustituidos y el uso de los mismos